Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0022 Transporter Info | ||||
| Gene Name | SLC15A2 | ||||
| Protein Name | Peptide transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs2257212 | ||||
| Site of GPD | chr3:121924957 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>G / C>T | ||||
| Minor Allele Frequency | T=0.4519/2263 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Sorafenib | Drug Info | Hepatocellular Carcinoma | Correlated with the decreased progression-free survival in patients (compare with Genotypes CT + TT) | [ 1] | |
| References | |||||
| 1 | SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget. 2015 Jun 30;6(18):16449-60. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.